A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Hoffmann-La Roche
Hoffmann-La Roche
M.D. Anderson Cancer Center
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Hoffmann-La Roche
Hoffmann-La Roche
Rutgers, The State University of New Jersey
University of Pittsburgh
Genentech, Inc.
Palleos Healthcare GmbH
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
Exelixis
CHA University
Exelixis
Hoffmann-La Roche
Dana-Farber Cancer Institute
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Washington University School of Medicine
NeoImmuneTech
National Cancer Institute (NCI)
G1 Therapeutics, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
SCRI Development Innovations, LLC
Affimed GmbH
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche